💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Montelukast

CHEMBL787 Phase 4 승인됨 Small molecule
Half-Life
2.7-5.5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
586.2 g/mol
LogP
7.7
Phase
4

This medication blocks leukotriene receptors, reducing airway inflammation and constriction in the lungs and relieving allergy symptoms in the nose and skin. It is taken once daily by mouth to prevent asthma attacks and treat allergic rhinitis and hives.

분자량

586.1800 g/mol

LogP

7.70

TPSA

95.70 Ų

리핀스키 5의 법칙

불통과

치료 영역

Ovarian Cancer Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Asthma Chronic Obstructive Pulmonary Disease Generalized Anxiety Disorder Oncology Gastroesophageal Reflux Disease Multiple Sclerosis Obesity Type 2 Diabetes Breast Cancer Atopic Dermatitis Chronic Pain Hepatitis C Colorectal Cancer

약물 분류

R — R - Respiratory System

작용 기전

Selective leukotriene D4 receptor antagonist.

Pharmacokinetics (PK)

Half-Life 2.7-5.5 hours

Pharmacodynamics (PD)

기전

Selective leukotriene D4 receptor antagonist.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C35H36ClNO3S

                    

                    
                    

                        
HBD / HBA

                        
2 / 5

                    

                    
                    

                        
회전 가능 결합

                        
12

                    

                    
                    
                    

                        
무거운 원자

                        
41

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            PTGS2 (Cyclooxygenase-2)
                            Antagonist
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            PPARG (Peroxisome Proliferator-Activated Receptor Gamma)
                            Other
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Montelukast + Phenytoin
                            
                        

                        
                        
Phenytoin, a potent CYP inducer, can increase the metabolism of montelukast, potentially reducing its plasma levels and therapeutic efficacy.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Montelukast + Fluconazole
                            
                        

                        
                        
Fluconazole inhibits CYP2C8-mediated metabolism of montelukast, modestly increasing montelukast plasma concentrations; the clinical impact is generally minor given montelukast's wide therapeutic index.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
This medication blocks leukotriene receptors, reducing airway inflammation and constriction in the lungs and relieving allergy symptoms in the nose and skin. It is taken once daily by mouth to prevent asthma attacks and treat allergic rhinitis and hives.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective leukotriene D4 receptor antagonist.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Montelukast: Half-life: 2.7-5.5 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Montelukast is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Albuterol
                            Small molecule
                        
                        
                        
                            Cetirizine
                            Small molecule
                        
                        
                        
                            Loratadine
                            Small molecule
                        
                        
                        
                            Diphenhydramine
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL787.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5281040.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.